GSKGSK plc
Is it safe?
Nothing alarming, nothing pristine: comfortable debt (A) and typical volatility.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -38% · now 23% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can GSK take a bad year?
GSK plc carries $14.3B of net debt at 1.40× EBITDA: a load its earnings can carry.
Net debt · as at FY2025 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 1.40×
Net debt / EBITDA · 2.00× a year ago · the load is coming down
- Interest cover
- 11.3×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 27%
Annualised volatility · about as steady as the market itself
Details›
- Total debtFY2025
- $17.7B
- Cash and short-term investments
- $3.40B
- Net debt
- $14.3B
- EBITDA, trailing twelve months
- $10.2B
- Operating profit, trailing twelve months
- $7.93B
- Debt / equity
- 1.08×
- Total debt / EBITDA
- 1.73×
- Annualised volatilitytwo years of daily moves
- 27%
- Worst drawdown on file
- −38%
- Below its 52-week high
- 23%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, General
Ranks #3 of 7 by RyuScore